NCT07217054 Colonic Tissue Biopsy Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis or REM Sleep Behavior Disorder
| NCT ID | NCT07217054 |
| Status | Recruiting |
| Phase | — |
| Sponsor | CND Life Sciences |
| Condition | PARKINSON DISEASE (Disorder) |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-11-04 |
| Primary Completion | 2028-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2025-11-04 with a primary completion date of 2028-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn whether tissue samples taken from the colon during routine colonoscopy can detect signs of Parkinson's disease or REM Sleep Behavior Disorder (RBD). The main question it aims to answer is: Can doctors find a protein called alpha-synuclein in colon tissue samples from people with Parkinson's disease and RBD? Currently, Parkinson's disease is diagnosed by observing symptoms like tremors and movement problems and RBD by loss of muscle atonia during REM sleep, but by then the disease has already progressed significantly. Earlier detection could help doctors start treatment sooner.
Eligibility Criteria
Inclusion Criteria: 1. Relatively healthy men and women ≥40-99 years of age 2. Patients with a diagnosis of 1. Clinically confirmed PD or 2. Clinically confirmed RBD with no diagnosis of PD, DLB or MSA 3. Patients must have agreed to undergo a routine colonoscopy as part of their screening or surveillance for colon cancer or for diagnostic purposes for the exclusion of other GI diseases Exclusion Criteria: 1. Use of anticoagulants (Plavix or aspirin alone is allowed) 2. Under active treatment for colon cancer; 30-day post anti-cancer treatment allowed 3. Current, ongoing gastrointestinal illness 4. Recent intrabdominal surgery 5. Pregnant or planning to become pregnant before the scheduled colonoscopy 6. Significant cognitive impairment, as determined by study investigators
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07217054 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 99 Years, studying PARKINSON DISEASE (Disorder). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07217054 currently recruiting?
Yes, NCT07217054 is actively recruiting participants. Contact the research team at cwagner@ddabranford.com for enrollment information.
Where is the NCT07217054 trial being conducted?
This trial is being conducted at Branford, United States.
Who is sponsoring the NCT07217054 clinical trial?
NCT07217054 is sponsored by CND Life Sciences. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.